Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11698MR)

This product GTTS-WQ11698MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11698MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2660MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ8404MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ2843MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ1646MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ8400MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ8648MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ9677MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ9826MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW